Brought to you by 
Cempra nets $94mm via FOPO
29 Oct 2020
Executive Summary
Antibiotics developer Cempra Inc. netted $94mm through a follow-on offering of 4.17mm common shares at $24 each. Some of the proceeds will support the US launch of solithromycin for community-acquired bacterial pneumonia once the drug gets FDA approval. Additional funds will help additional development of solithromycin for gonorrhea, and Taksta for acute bacterial skin and skin structure infections and refractory bone and joint infections.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cempra nets $94mm via FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice